Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

King of Prussia, Pennsylvania 19406


Purpose:

Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.


Study summary:

Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.


Criteria:

- Diagnosis of candidemia and/or other forms of invasive candidiasis. - Should not have received greater than 48 hours of systemic antifungal therapy. - Life expectancy should be greater than 72 hours. - Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment


NCT ID:

NCT00056368


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

King of Prussia, Pennsylvania 19406
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 13, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.